Sudeep Pharma Reports Q1 Financial Results for FY26; Revenue Stands at 15,827.05 Lakhs
Sudeep Pharma Limited has announced its unaudited consolidated and standalone financial results for the first quarter ended June 30, 2026. The company's Board of Directors approved these results during a meeting held on August 4, 2026.The consolidated results showed strong performance across the group’s operations. Total Income for the quarter reached 16,371.59 lakhs, while Revenue from operations was reported at 15,827.05 lakhs. Profit for the period stood at 4,058.69 lakhs.
The unaudited consolidated financial results include data spanning various entities within the group. The company also noted that it completed a final purchase price allocation (PPA) during this quarter regarding the acquisition of Nutrition Supplies & Services (Ireland) Limited (NSS), which was initially entered into agreement on April 9, 2025, for 85% equity interest at a purchase price of Rs 12,857.63 Lakhs.
Financial Performance Highlights (Consolidated and Standalone)
Key financial metrics for the quarter ended June 30, 2026, are presented below:| Metric | Consolidated Results | Standalone Results |
|---|---|---|
| Total Income | 16,371.59 lakhs | 11,508.36 lakhs |
| Revenue from Operations | 15,827.05 lakhs | 10,568.33 lakhs |
| Profit for the Period | 4,058.69 lakhs | 3,382.85 lakhs |
Segment Operational Overview
In accordance with Ind AS 108 - Operating Segments, Sudeep Pharma Limited operates across two primary segments: Pharmaceutical, food and nutrition, and Speciality ingredients.For the quarter ended June 30, 2026, segment revenues totaled as follows:
| Segment | Revenue from Operations (Lakhs) |
|---|---|
| Pharmaceutical, food and nutrition | 10,841.37 |
| Speciality ingredients | 4,985.68 |
IPO Proceeds and Utilization
The company reported that it received a net proceeding of INR 8,833.59 lakhs from the fresh issue of equity shares, which occurred after listing on stock exchanges in November 2025.The utilization plan for these net proceeds included:
- Capital expenditure toward machinery procurement for the production line at the Nandesari Facility, amounting to 7,581.40 lakhs.
- General corporate purposes, amounting to 1,252.19 lakhs.
As of June 30, 2026, the unutilised net proceeds from the IPO amounted to 7,545.63 lakhs.
SUDEEPPHRM Stock Price Movement
Sudeep Pharma Limited closed today after rallying, registering a gain of 0.62% or ₹5.40 and settling at ₹871.80 in market action. The stock saw robust activity during the session, with total traded volume reaching 131,410 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.